Tudor Investment Corp ET AL Acquires Shares of 31,641 Masimo Corporation $MASI

Tudor Investment Corp ET AL acquired a new stake in Masimo Corporation (NASDAQ:MASI) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 31,641 shares of the medical equipment provider’s stock, valued at approximately $4,669,000.

Other hedge funds have also recently modified their holdings of the company. Smartleaf Asset Management LLC increased its position in shares of Masimo by 80.0% in the third quarter. Smartleaf Asset Management LLC now owns 306 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 136 shares during the period. Advisory Services Network LLC purchased a new position in shares of Masimo in the third quarter valued at about $46,000. Danske Bank A S purchased a new position in shares of Masimo in the third quarter valued at about $59,000. Clearstead Advisors LLC increased its position in shares of Masimo by 18.4% in the third quarter. Clearstead Advisors LLC now owns 470 shares of the medical equipment provider’s stock valued at $69,000 after acquiring an additional 73 shares during the period. Finally, Quantbot Technologies LP purchased a new position in shares of Masimo in the second quarter valued at about $86,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Wolfe Research cut shares of Masimo from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 19th. Wells Fargo & Company upgraded shares of Masimo to a “hold” rating in a research report on Wednesday, March 18th. BTIG Research cut shares of Masimo from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 18th. Stifel Nicolaus set a $180.00 price objective on shares of Masimo in a research report on Tuesday, February 17th. Finally, Piper Sandler cut shares of Masimo from an “overweight” rating to a “hold” rating and set a $180.00 price objective on the stock. in a research report on Tuesday, February 17th. Eight analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Masimo has a consensus rating of “Reduce” and a consensus price target of $181.17.

Masimo Trading Down 0.2%

Shares of MASI opened at $178.30 on Thursday. The firm’s 50-day moving average price is $165.81 and its 200-day moving average price is $150.23. The firm has a market capitalization of $9.58 billion, a price-to-earnings ratio of -16.92, a PEG ratio of 1.81 and a beta of 1.20. The company has a current ratio of 2.49, a quick ratio of 1.47 and a debt-to-equity ratio of 0.72. Masimo Corporation has a 1-year low of $125.94 and a 1-year high of $179.00.

Masimo Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.